Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Medexus Pharmaceuticals Inc. is a Canadian-based specialty pharmaceutical company with a strong North American focus, dedicated to acquiring, licensing, and commercializing innovative and established prescription and over-the-counter (OTC) therapeutic products. The company's mission is to provide patients with access to vital medicines that address unmet medical needs, particularly in areas such as rheumatology, auto-immune diseases, oncology, and hematology. Medexus operates with a lean and agile business model, leveraging strategic partnerships and a robust commercial infrastructure in both Canada and the United States to bring valuable treatments to market efficiently.
Serves as the registered global head office, overseeing corporate strategy, finance, Canadian commercial operations, regulatory affairs, and overall group governance for Medexus.
Located in a modern business park environment, designed for operational efficiency. Specific architectural details are not publicly emphasized, typical for a functional corporate office supporting a specialty pharmaceutical company.
Fosters a collaborative and agile work environment, focused on bringing innovative pharmaceutical products to market. Emphasizes expertise, ethical practices, and a commitment to patient needs in the North American healthcare landscape.
Represents Medexus's Canadian operational hub and strategic center, anchoring its North American presence and commitment to the Canadian market, while coordinating with U.S. operations.
Medexus Pharmaceuticals primarily operates and commercializes products within North America, specifically Canada and the United States. While its direct operational footprint is concentrated in these two countries, its global presence is extended through strategic in-licensing agreements with international pharmaceutical partners, allowing Medexus to bring innovative global products to the North American market. Functions supported globally include business development (sourcing products worldwide), regulatory affairs (managing FDA and Health Canada approvals), and supply chain management in coordination with international manufacturing partners.
2963 Glen Drive, Suite 212
Coquitlam
British Columbia
Canada
Address: 20 N. Wacker Drive, Suite 1438, Chicago, IL 60606, USA
To spearhead Medexus's commercial activities and expansion in the United States, focusing on maximizing the potential of its existing products and identifying new opportunities for growth within the U.S. healthcare system.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Medexus Pharmaceuticals' leadership includes:
Medexus Pharmaceuticals has been backed by several prominent investors over the years, including:
In the past year, Medexus Pharmaceuticals has strengthened its leadership team with key appointments, including a new Chief Financial Officer and a new Vice President of Regulatory Affairs & Quality Assurance, while also seeing a transition in the CFO role.
Discover the tools Medexus Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Medexus Pharmaceuticals Inc. commonly utilizes an email format consisting of the employee's first initial followed by their full last name, then the @ symbol and the company domain. While this is a prevalent pattern, other formats could potentially be in use within the organization.
f[last]@medexus.com
Format
kdentremont@medexus.com
Example
85%
Success rate
GlobeNewswire • May 1, 2024
Medexus announced an amendment to its existing credit facility with BMO Bank of Montreal. This amendment provides the company with increased financial flexibility to support its ongoing operations, product commercialization, and strategic growth initiatives....more
GlobeNewswire • February 13, 2024
Medexus reported its financial results for the third quarter of fiscal year 2024, ended December 31, 2023. The company highlighted revenue performance, updates on its key products such as Rupall and IXINITY, and progress on its commercial and operational objectives....more
GlobeNewswire • August 14, 2023
Medexus announced the appointment of Marcel Konrad as its new Chief Financial Officer, effective August 28, 2023, succeeding Roland Boivin. Konrad brings significant experience in finance and the pharmaceutical industry to Medexus....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Medexus Pharmaceuticals, are just a search away.